Valion Bio Completes 200-Liter Non-GMP Entolimod Production Run
Valion Bio's wholly owned subsidiary, Velocity Bioworks, completed a 200-liter non-GMP production run of Entolimod from May through June 2026 at its San Antonio, Texas facility. The run achieved approximately 27% higher productivity compared with historical manufacturing data, and the resulting drug substance met all predefined acceptance criteria for the quality attributes assessed. Drug product filled in June 2026 is supplying Valion Bio's ongoing Entolimod study, which is fully funded by NIAID/RNCP under an i...
Key takeaways
Velocity Bioworks completed a 200-liter non-GMP Entolimod production run at its San Antonio, Texas facility from May through June 2026.
The run achieved approximately 27% higher productivity compared with historical manufacturing data.
The resulting drug substance met all predefined acceptance criteria for the quality attributes assessed.
Drug product filled in June 2026 is supplying Valion Bio's ongoing Entolimod study.
The ongoing study is fully funded by NIAID/RNCP under an interagency agreement with USU/AFRRI.
The 200-liter run followed a 50-liter production run completed in January 2026 and increased production scale fourfold.
Valion Bio expects to apply learnings from the run to plans for future CGMP manufacturing and continues to evaluate strategic alternatives for Velocity Bioworks.
Key metrics
Primary source
TickerStar generated this brief from an official company, investor-relations, earnings-call, or regulatory source. Review the primary material before making an investment decision.
Open Investor relationsFollow VBIO in real time
Get material earnings, filing, IR, and earnings-call alerts by email.